All Updates

All Updates

icon
Filter
Partnerships
Metabolon and SERA Study partner to identify rheumatoid arthritis biomarkers for improving treatment
Precision Medicine
Aug 28, 2024
This week:
Management news
6K Additive awarded project to develop C-103 powder for additive manufacturing
Additive Manufacturing
Sep 27, 2024
Partnerships
WAAM3D partners with Innovative Space Carrier, Cranfield University, and Aichi Sangyo for space transport development
Additive Manufacturing
Sep 19, 2024
Product updates
Microsoft launches Face Check with Microsoft Entra Verified ID
Facial Recognition
Sep 11, 2024
Funding
3DEO raises USD 3.5 million in strategic investment from Mizuho Bank
Additive Manufacturing
Sep 6, 2024
Product updates
HyperWrite launches open-source AI model Reflection 70 billion
Generative AI Applications
Sep 5, 2024
Product updates
Google begins US rollout of AI-powered Ask Photos feature
Generative AI Applications
Sep 5, 2024
Funding
Management news
HDAX Therapeutics raises USD 3.2 million in seed funding to progress pipeline and advance preclinical candidates into trials
Precision Medicine
Sep 5, 2024
Partnerships
Sequentify partners with Dexter to expand genomic diagnostics in Romania
Precision Medicine
Sep 5, 2024
Partnerships
Elevate partners with Cultivatd for European expansion
Vertical Farming
Sep 5, 2024
Product updates
Moolec confirms harvest of its genetically engineered plant-grown products
Crop Biotech
Sep 5, 2024
Precision Medicine

Precision Medicine

Aug 28, 2024

Metabolon and SERA Study partner to identify rheumatoid arthritis biomarkers for improving treatment

Partnerships

  • Metabolon has partnered with the Scottish Early Rheumatoid Arthritis (SERA) Study to identify possible rheumatoid arthritis biomarkers.

  • The partnership aims to discover circulating small molecules that could be used to predict a patient's risk of developing rheumatoid arthritis, track the progression of the illness, and monitor their response to treatment. Using Metabolon's extensive library of small molecules in combination with SERA's well-curated patient cohort, the initiative plans to incorporate metabolomic data with clinical and genomic information.

  • The overall goal is to understand better the underlying molecular mechanisms of rheumatoid arthritis, which could inform improved diagnostic approaches and treatment strategies.

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.